Argen-X (1AE) - Net Assets
Based on the latest financial reports, Argen-X (1AE) has net assets worth €6.10 Billion EUR (≈ $7.13 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.18 Billion ≈ $8.39 Billion USD) and total liabilities (€1.08 Billion ≈ $1.26 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 1AE financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.10 Billion |
| % of Total Assets | 84.95% |
| Annual Growth Rate | 74.7% |
| 5-Year Change | 302.99% |
| 10-Year Change | N/A |
| Growth Volatility | 132.67 |
Argen-X - Net Assets Trend (2016–2024)
This chart illustrates how Argen-X's net assets have evolved over time, based on quarterly financial data. Also explore how large is Argen-X's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Argen-X (2016–2024)
The table below shows the annual net assets of Argen-X from 2016 to 2024. For live valuation and market cap data, see 1AE stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €5.50 Billion ≈ $6.43 Billion |
+34.19% |
| 2023-12-31 | €4.10 Billion ≈ $4.79 Billion |
+45.63% |
| 2022-12-31 | €2.81 Billion ≈ $3.29 Billion |
+11.03% |
| 2021-12-31 | €2.53 Billion ≈ $2.96 Billion |
+85.74% |
| 2020-12-31 | €1.36 Billion ≈ $1.60 Billion |
+29.85% |
| 2019-12-31 | €1.05 Billion ≈ $1.23 Billion |
+95.16% |
| 2018-12-31 | €538.39 Million ≈ $629.44 Million |
+56.09% |
| 2017-12-31 | €344.93 Million ≈ $403.26 Million |
+444.28% |
| 2016-12-31 | €63.37 Million ≈ $74.09 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Argen-X's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 149931200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €7.07 Billion | 128.59% |
| Total Equity | €5.50 Billion | 100.00% |
Argen-X Competitors by Market Cap
The table below lists competitors of Argen-X ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Roche Holding AG
SW:RO
|
$44.05 Billion |
|
Datadog Inc
NASDAQ:DDOG
|
$44.23 Billion |
|
Rockwell Automation Inc
NYSE:ROK
|
$44.40 Billion |
|
Banco Santander Brasil SA ADR
NYSE:BSBR
|
$44.45 Billion |
|
Celestica Inc.
TO:CLS
|
$43.91 Billion |
|
Unimicron Technology Corp
TW:3037
|
$43.80 Billion |
|
Yum! Brands Inc
NYSE:YUM
|
$43.78 Billion |
|
Bayer AG NA
XETRA:BAYN
|
$43.70 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Argen-X's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,097,507,000 to 5,498,283,000, a change of 1,400,776,000 (34.2%).
- Net income of 833,040,000 contributed positively to equity growth.
- Other factors increased equity by 567,736,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €833.04 Million | +15.15% |
| Other Changes | €567.74 Million | +10.33% |
| Total Change | €- | 34.19% |
Book Value vs Market Value Analysis
This analysis compares Argen-X's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 61.13x to 7.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €10.72 | €655.20 | x |
| 2018-12-31 | €14.97 | €655.20 | x |
| 2019-12-31 | €24.57 | €655.20 | x |
| 2020-12-31 | €28.68 | €655.20 | x |
| 2021-12-31 | €49.05 | €655.20 | x |
| 2022-12-31 | €50.79 | €655.20 | x |
| 2023-12-31 | €69.22 | €655.20 | x |
| 2024-12-31 | €90.49 | €655.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Argen-X utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.15%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 38.03%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.13x
- Recent ROE (15.15%) is above the historical average (-15.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -33.73% | -145.27% | 0.14x | 1.67x | €-27.71 Million |
| 2017 | -8.14% | -77.10% | 0.10x | 1.08x | €-62.57 Million |
| 2018 | -12.38% | -310.22% | 0.04x | 1.07x | €-120.48 Million |
| 2019 | -15.51% | -233.53% | 0.05x | 1.36x | €-268.04 Million |
| 2020 | -38.77% | -1452.09% | 0.02x | 1.36x | €-665.36 Million |
| 2021 | -16.11% | -82.10% | 0.17x | 1.12x | €-661.69 Million |
| 2022 | -25.22% | -172.76% | 0.13x | 1.11x | €-990.96 Million |
| 2023 | -7.20% | -24.06% | 0.27x | 1.11x | €-704.80 Million |
| 2024 | 15.15% | 38.03% | 0.35x | 1.13x | €283.21 Million |
Industry Comparison
This section compares Argen-X's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $716,276,481
- Average return on equity (ROE) among peers: -68.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Argen-X (1AE) | €6.10 Billion | -33.73% | 0.18x | $44.01 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more